Wegovy tablets vs Wegovy injection — which is right for you?

# Wegovy tablets vs Wegovy injection — which is right for you?

Oral Wegovy received MHRA approval on 11 June 2026, meaning that for the first time in the UK, semaglutide — the active ingredient in Wegovy — is available in tablet form. That raises a question that anyone who has been considering or using Wegovy will now be asking: how does the tablet compare to the injection, and does it make sense to switch?

This guide sets out the key differences in plain terms: weight loss evidence, how each is taken, cost, side effect profiles, availability, and the factors that might make one a better fit than the other for any given person. The goal is not to recommend one over the other — that decision belongs with your prescriber — but to give you an accurate basis for that conversation.

> Wegovy tablets and Wegovy injection are both prescription-only medicines. Always consult a qualified healthcare professional before starting or changing treatment. Do not self-switch between formulations without prescriber guidance.

—

## The same active ingredient, different formulations

Both Wegovy tablets and Wegovy injection contain semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist developed by Novo Nordisk. Semaglutide works by mimicking the GLP-1 hormone your body naturally produces after eating — it enhances insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite by acting on receptors in the brain’s satiety centres.

The active ingredient is identical. The difference is how that ingredient reaches your bloodstream, in what quantity, and on what schedule.

—

## How each is taken

**Wegovy injection:** Administered once weekly via a pre-filled autoinjector pen, subcutaneously (under the skin, typically in the abdomen, thigh, or upper arm). The injection can be given at any time of day and with or without food. No fasting is required around dosing time.

**Wegovy tablets:** Taken once daily, orally. Requires an empty stomach — 30 minutes before any food or drink other than plain water (maximum 120ml). The tablet must be swallowed whole with that small amount of water and nothing else.

The fasting requirement is the single most important practical distinction between the two formulations. Injectable semaglutide has no dietary restriction associated with dosing time. The tablet requires a daily 30-minute fasting window, every morning (or at whatever time of day you choose to take it).

—

## Weight loss results: closer than you might expect

When people think of injectable versus oral versions of a medicine, the assumption is often that the injection is stronger. The clinical trial data for semaglutide challenges this assumption.

**OASIS 2 trial (oral semaglutide 25mg daily):** mean body weight reduction of **15.1%** over 68 weeks, in adults with BMI ≥30 (or ≥27 with a weight-related health condition), all with structured lifestyle counselling.

**STEP 1 trial (injectable semaglutide 2.4mg weekly):** mean body weight reduction of approximately **14.9%** over 68 weeks, in a similar adult population with lifestyle counselling.

The difference — 0.2 percentage points — is not clinically meaningful. Within the limitations of cross-trial comparison (different populations, different recruitment periods, slightly different study designs), oral and injectable semaglutide appear to produce very similar average weight loss outcomes.

This finding surprised many clinicians, because oral semaglutide has a much lower bioavailability than the injection. The solution is dose: the tablet contains 25mg of semaglutide, compared to 2.4mg weekly for the injection. The much higher oral dose compensates for the lower proportion that reaches the bloodstream, producing comparable systemic exposure.

What this means practically: neither formulation should be chosen over the other purely on the grounds of expected weight loss. The results are broadly equivalent.

—

## Bioavailability: why the doses look so different

Injectable semaglutide delivered subcutaneously has bioavailability approaching 100% — virtually all of the dose reaches the bloodstream. Oral semaglutide, despite the SNAC absorption technology that enables it, has approximately 1% oral bioavailability. The SNAC compound creates a localised absorption-enhancing environment in the stomach, but the majority of each tablet is still not absorbed.

This is why the tablet dose is 25mg and the injection dose is 2.4mg. The net amount of semaglutide reaching the circulation is intended to be similar; the route just requires a much higher starting quantity.

This bioavailability difference also explains why the fasting window matters so much for the tablet. Food, drink, and gastric secretions can further reduce absorption significantly — potentially halving the effective dose. The injection bypasses this entirely.

—

## Needle-free vs once-weekly: the convenience trade-off

**For people who dislike or fear injections:** the tablet is the obvious choice. Needle phobia is a significant barrier to treatment for a meaningful proportion of patients. Daily tablets have a familiar, low-anxiety administration method.

**For people who prefer less frequent dosing:** the injection’s once-weekly schedule has real appeal. One injection per week requires less daily routine attention than one tablet every morning. Many people find the weekly habit easier to sustain than a daily one.

**For people who can struggle with morning routines:** the tablet’s 30-minute fasting window every morning can be a genuine barrier. If you have young children and a chaotic morning routine, if you work irregular early shifts, or if you simply find the pre-breakfast window difficult to protect consistently, the injection’s absence of dosing restrictions may be practically superior.

There is no universally correct answer here. The question to ask is: which administration method am I genuinely more likely to follow consistently over the long term?

—

## Cost: a significant practical difference

This is an area where the tablet has a clear advantage in the UK private market.

**Wegovy injection (private, UK):** costs approximately £200 or more per month for the 2.4mg maintenance dose. Prices vary by provider but the injection has consistently been expensive relative to many patients’ budgets.

**Oral Wegovy (private, UK, as of June 2026):** prices among verified UK providers with pre-orders open range from **£64 per month (Bolt Pharmacy) to £113.95 per month (Pharmacy2U)** at the starting 1.5mg dose. Pricing at the maintenance 25mg dose is expected to be higher — check current verified prices at CompareWegovyPrices.co.uk for the latest data.

Even at higher maintenance doses, oral Wegovy is expected to be substantially less expensive per month than the injection in the private market. For people self-funding treatment without insurance, this is a significant consideration.

**On the NHS:** injectable Wegovy has a restricted NHS pathway, available through specialist weight management services for patients with BMI ≥40 (or ≥35 with serious co-morbidities) following referral. Oral Wegovy has not yet been recommended for NHS use. NHS availability of the tablet may develop over time, but is not currently established.

—

## Availability in the UK

**Wegovy injection:** has been available in the UK for longer and has an established supply chain. NHS availability (restricted) and private prescribing are both possible, though supply constraints have been a persistent issue with injectable semaglutide products.

**Wegovy tablets:** MHRA-approved since 11 June 2026, with commercial launch expected July 2026. As of the date of this guide, 7 UK providers have pre-orders open. Supply is building and availability is expected to grow through the latter half of 2026.

—

## Side effects: broadly similar, some practical differences

The GI side effect profile of oral and injectable semaglutide is broadly similar — nausea, vomiting, diarrhoea, constipation, reflux, and burping are common with both. Serious rare risks (pancreatitis, gallbladder events, thyroid considerations) apply to both formulations.

One practical distinction: the injection delivers a weekly bolus that creates a peak blood level followed by a gradual decline. Many people on the injection notice that side effects cluster in the day or two after injection, then ease. The daily tablet produces more consistent blood levels day to day, but absorption variability (due to the fasting requirement) can mean more unpredictable nausea on days when the fasting window was imperfect.

Neither formulation has a clearly superior side effect profile — the differences are subtle and individual responses vary considerably.

—

## Who might choose the tablet

– People with needle phobia or who strongly prefer not to self-inject
– People for whom monthly cost is a significant factor and the lower tablet price makes treatment feasible where the injection would not be
– People new to GLP-1 medicines who have not yet started either formulation
– People who can reliably protect a 30-minute fasting window each morning as a consistent daily habit
– People outside the NHS pathway who are self-funding privately

—

## Who might stay with (or choose) the injection

– People already established on injectable Wegovy who are responding well and tolerating it comfortably
– People whose morning routine makes daily fasting consistently difficult to observe
– People who find weekly dosing easier to maintain than daily dosing
– People who qualify for NHS injectable Wegovy and would incur significant additional cost by switching to private oral treatment
– People whose prescriber has specific clinical reasons for preferring the injectable form

—

## Can you switch from injection to tablet?

Switching between formulations is possible in principle, but must be done with prescriber guidance. The dose equivalence is not straightforward (given the very different doses involved), and switching during a period of active dose escalation requires careful management.

**Do not self-switch.** If you are currently on injectable Wegovy and wish to explore switching to the tablet, the appropriate step is to raise it with your prescriber at your next review. They can advise on timing, dose mapping, and monitoring requirements for a safe transition.

Similarly, if you are on oral Wegovy and wish to consider switching to the injection — perhaps because the fasting window is proving unworkable — that is also a prescriber conversation.

—

## The decision framework: a practical summary

| Factor | Tablet | Injection |
|—|—|—|
| Dosing frequency | Once daily | Once weekly |
| Fasting requirement | 30 min daily | None |
| Administration | Swallow tablet | Self-inject subcutaneously |
| Average weight loss (trial data) | ~15.1% (OASIS 2, 68 weeks) | ~14.9% (STEP 1, 68 weeks) |
| Private cost (approximate) | £64–£114/month (starting dose) | ~£200+/month |
| NHS availability | Not currently | Restricted (specialist services) |
| Approved in UK | Yes (11 June 2026) | Yes (longer established) |
| Suitable for needle phobia | Yes | No |

The table does not make the decision for you — it frames the trade-offs so that you can have an informed conversation with your prescriber about which formulation better fits your clinical needs, practical circumstances, and personal preferences.

—

## Frequently asked questions

### Does oral Wegovy cause as much weight loss as the injection?

The clinical trial data suggests very similar average weight loss results. The OASIS 2 trial of oral semaglutide showed an average weight reduction of approximately 15.1% at 68 weeks, compared to approximately 14.9% in the STEP 1 trial of injectable Wegovy at the same timepoint. These trials involved different populations and cannot be directly compared, but the results place both formulations in a comparable range of effectiveness.

### Why is the Wegovy tablet dose so much higher than the injection dose?

The oral tablet contains 25mg of semaglutide compared to 2.4mg weekly for the injection, because the tablet has approximately 1% oral bioavailability — the vast majority of each tablet is not absorbed. The much higher oral dose compensates for lower absorption to produce a similar amount of semaglutide in the bloodstream. This is why the tablet requires a strict fasting protocol: food and drink reduce absorption further.

### Is oral Wegovy cheaper than the injection in the UK?

Yes, significantly so in the current private market. UK providers with pre-orders open for oral Wegovy (as of June 2026) are listing prices from £64 per month at the starting dose, compared to approximately £200 or more per month for injectable Wegovy. Prices vary by provider and dose level — check CompareWegovyPrices.co.uk for current verified pricing.

### Can I switch from Wegovy injection to the tablet?

Switching formulations is possible, but must be done under prescriber guidance. The dose relationship between the two formulations is not a simple conversion, and a supervised transition is important for safety and to maintain therapeutic benefit. Do not self-switch between injectable and oral semaglutide.

### Is Wegovy tablets available on the NHS?

Not currently. Injectable Wegovy has a restricted NHS pathway through specialist weight management services. Oral Wegovy received MHRA approval in June 2026 and is available privately; NHS commissioning of the tablet formulation has not been established at the time of writing. NHS availability may develop over time.

### Which is better for someone who hates needles?

The tablet is the appropriate choice for anyone with significant needle phobia or who strongly prefers not to self-inject. Both formulations contain the same active ingredient and produce broadly similar weight loss outcomes in clinical trials. Needle phobia is a legitimate clinical factor that your prescriber will take into account.

—

*This article is for informational purposes only and does not constitute medical advice. Wegovy tablets and Wegovy injection (semaglutide) are prescription-only medicines available in the UK. Always consult a registered UK healthcare professional before starting or changing any weight management treatment. Do not switch between formulations without prescriber guidance. CompareWegovyPrices.co.uk is not affiliated with Novo Nordisk.*